L. A. Mukha

Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia

Olga Vinogradova, М. М. Панкрашкина, L. A. Mukha, Anna L. Neverova et autres

Background. Thrombopoietin receptor agonists (TORAs), which can imitate the biological effect of thrombopoietin, have shown high efficacy in a number of clinical studies and real clinical practice in patients with resistant primary immune thrombocytopenia (IT). It seems extremely relevant to evaluate the …

ru (code pays fourni par la source)

Treatment opportunities for refractory immune thrombocytopenia

M. M. Pankraskina, Olga Vinogradova, Mikhail V. Chernikov, L. A. Mukha et autres

Background. Primary immune thrombocytopenia (ITP) is an orphan disease characterized by decreased platelet count in the peripheral blood which in some cases can cause bleeding of varying severity. Currently, the use of thrombopoietin receptor agonists (TPO-RAs) is recommended as the second line …

ru (code pays fourni par la source)

PF336 EVALUATION OF THROMBOPOIETIN‐RECEPTOR AGONISTS (TPO‐RAS) «STOP‐THERAPY» IN IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

Olga Vinogradova, M. Pankrashkina, N. Tkachenko, Mikhail V. Chernikov et autres

Background: For a number of years, it has been shown that TPO‐RAs are a highly effective therapy of ITP. Still, there are few published guidelines/recommendations addressing the management of ITP patients (pts) on TPO‐RAs after they achieve continuous remission. Aims: To evaluate …

ru (code pays fourni par la source)

Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice

В. И. Воробьев, Vera A. Zherebtsova, Egor I. Dubrovin, Liudmila A. Bychenkova et autres

Aim. To assess efficacy and toxicity of ibrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL). Materials & Methods. In this group of patients ibrutinib has been used since April 2016. Ibrutinib administration criteria were the age > 18 years and …

ru (code pays fourni par la source)

Промежуточные результаты проспективного наблюдательного исследования: 2-летний опыт применения ибрутиниба при рецидивах и рефрактерном течении мантийноклеточной лимфомы в реальной клинической практике

Воробьев Владимир Иванович, В. А. Жеребцова, Е И Дубровин, Л А Быченкова et autres

ЛИМФОИДНЫЕ ОПУХОЛИ Промежуточные результаты проспективного наблюдательного исследования: 2-летний опыт применения ибрутиниба при рецидивах и рефрактерном течении мантийноклеточной лимфомы в реальной клинической практике В.И.Воробьев, В.А.Жеребцова, Е.И.Дубровин, Л.А.Быченкова, Ю.Б.Кочкарева, Л.А.Муха, В.Л.Иванова, Н.К.Хуажева, В.В.Птушкин ГБУЗ «Городская клиническая больница им.С.П.Боткина ДЗМ», 2-й Боткинский пр-д, д. 5, …

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

Elena A. Dmitrieva, Mikhail Aleksandrovich Panteleev, E.L. Emelina, V. L. Ivanova et autres

Background & Aims. This paper presents the results of the observational study of ibrutinib in patients with chronic lymphocytic leukemia (CLL), conducted in SP Botkin Municipal Clinical Hospital. The main objective was the analysis of complications of ibrutinib and identification of factors, …

ru (code pays fourni par la source)

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

Е.С. Никитин, Е. А. Дмитриева, MA Panteleev, E.L. Emelina et autres

EA Nikitin1, EA Dmitrieva1, MA Panteleev2, EI Emelina3, VL Ivanova1, YuB Kochkareva1, EG Arshanskaya1, IE Lazarev1, EE Markova1, LA Mukha1, NG Novitskaya1, MM Pankrashkina1, VV Glazunova1, AV Shubina1, SA Chernysh1, NK Khuazheva1, EV Naumova4, SA Lugovskaya4, ME Pochtar’4, TN Obukhova5, OYu Vinogradova1, …

ru (code pays fourni par la source)

Ибрутиниб в лечении рефрактерного хронического лимфолейкоза

Evgenii Aleksandrovich Nikitin, Elena A. Dmitrieva, М.А. Пантелеев, Elena Ivanovna Emelina et autres